GlassScriptPrepare for your visit
Quillan Huang
Internal Medicine · Houston, TX · NPI 1215270947
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$8,177.74
in general payments reported to CMS, 2019-2025 · $855 in 2025
The $855 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Who reported paying
General payments only, top 6 by amount.
- Jazz Pharmaceuticals INC. $1,907.15
- Takeda Pharmaceuticals U.S.A., INC. $1,666.93
- Daiichi Sankyo INC. $850.00
- Astrazeneca Pharmaceuticals LP $821.44
- Beigene USA, INC. $675.00
- Glaxosmithkline, LLC. $430.00
Drugs and devices associated with these payments
Zepzelca Brukinsa Vanflyta Tagrisso Xt Cdx Imfinzi Ultomiris Keytruda Lenvima Monjuvi Enhertu Xalkori
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Quillan Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/511885/quillan-huang